At a glance
ClinicalIndex Comparison RecordN/ACompleted· 49 enrolled
Drug / intervention
loteprednol 0.5% ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Outcomes and Evaluation of Lotemax (Loteprednol Ophthalmic Solution ) 0.5% QID for Treatment of Ocular Inflammation Associated With Cataract Surgery
In Brief
An observational study evaluating loteprednol 0.5% ophthalmic solution for Pseudophakia and Inflammation. Completed, enrolled 49 participants across 1 site.
Detailed Summary
Investigate the intraocular pressure(pressure inside the eye) of patients who are treated with Lotemax after undergoing cataract surgery.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPseudophakia, Inflammation
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedApr 2011
Primary CompletionSep 2013
TodayJul 2026
First PostedApr 29, 2011
Enrollment StartApr 1, 2011
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.2 years ago
Interventions
loteprednol 0.5% ophthalmic solutiondrug
Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.